NCT06719882

Brief Summary

The aim of study is to evaluate the quality of vision after bilateral Vivity or Vivity toric EDOF IOLs implantation in Taiwan.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Dec 2022

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 15, 2022

Completed
1.9 years until next milestone

First Submitted

Initial submission to the registry

November 10, 2024

Completed
26 days until next milestone

First Posted

Study publicly available on registry

December 6, 2024

Completed
25 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2024

Completed
Last Updated

December 6, 2024

Status Verified

December 1, 2024

Enrollment Period

2 years

First QC Date

November 10, 2024

Last Update Submit

December 5, 2024

Conditions

Keywords

Intraocular lensExtended depth of focus

Outcome Measures

Primary Outcomes (1)

  • Visual acuity (LogMAR)

    Uncorrected binocular far, intermediate and near visual acuity. Corrected binocular far, intermediate and near visual acuity.

    From enrollment to the end of treatment at 3 months

Other Outcomes (1)

  • Intermediate reading speed (seconds)

    From enrollment to the end of treatment at 3 months

Study Arms (1)

Vivity/Vivity toric

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients who intended for sequential bilateral cataract surgery and implanted with Vivity/Vivity IOL would be asked to include in this study.

You may qualify if:

  • Patients with age-related cataract requiring surgery treatment
  • Patient who received bilateral, uneventful implantation of Vivity IOLs
  • Patient's IOL power is between 10-30D, and T2-T6 for toric correction
  • Cataract grade 0\~3 based on the Wisconsin cataract grading system

You may not qualify if:

  • Cataract grade 4\~5 based on the Wisconsin cataract grading system
  • Patient's IOL power is outside of 10-30D or T2-T6 for toric correction
  • Patient with the following ocular comorbidities:
  • Corneal opacities or irregularities;
  • Severe dry eye;
  • Amblyopia;
  • Glaucoma;
  • Non-dilating pupil;
  • History of intraocular surgery, laser therapy, or retinopathy;
  • Optic nerve or macular diseases;
  • Uncontrolled diabetic mellitus or systemic immune disease;
  • Refusal or unable to maintain follow-up

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Taiwan Nobel Eye Clinic

Taipei, Taiwan

Location

Related Publications (2)

  • Kandavel R, Colvard M, Dredge J, Bayle M, Alam T, Snyder J, Hall B. Comparative Study Between Non-Diffractive Extended Depth of Focus and Monofocal Intraocular Lenses. Clin Ophthalmol. 2023 Apr 14;17:1161-1168. doi: 10.2147/OPTH.S402069. eCollection 2023.

  • Hovanesian JA, Jones M, Allen Q. The Vivity Extended Range of Vision IOL vs the PanOptix Trifocal, ReStor 2.5 Active Focus and ReStor 3.0 Multifocal Lenses: A Comparison of Patient Satisfaction, Visual Disturbances, and Spectacle Independence. Clin Ophthalmol. 2022 Jan 18;16:145-152. doi: 10.2147/OPTH.S347382. eCollection 2022.

MeSH Terms

Conditions

Cataract

Condition Hierarchy (Ancestors)

Lens DiseasesEye Diseases

Study Officials

  • ChaoKai Chang, Ph.D.

    Taiwan Nobel Eye Clinic

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
3 Months
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Doctor

Study Record Dates

First Submitted

November 10, 2024

First Posted

December 6, 2024

Study Start

December 15, 2022

Primary Completion

December 31, 2024

Study Completion

December 31, 2024

Last Updated

December 6, 2024

Record last verified: 2024-12

Data Sharing

IPD Sharing
Will not share

Locations